Duopharma Biotech
Duopharma Biotech Berhad, a leading player in the pharmaceutical industry, is headquartered in Malaysia (MY) and operates extensively across Southeast Asia. Founded in 1970, the company has established itself as a key provider of generic and innovative medicines, focusing on areas such as oncology, cardiology, and anti-infectives. With a commitment to quality and affordability, Duopharma Biotech offers a diverse range of products, including prescription medications and over-the-counter solutions, distinguished by their rigorous adherence to international standards. The company has achieved significant milestones, including the introduction of Malaysia's first biosimilar product, solidifying its market position as a pioneer in biopharmaceuticals. Recognised for its contributions to healthcare, Duopharma Biotech continues to innovate, ensuring access to essential medicines while maintaining a strong commitment to sustainability and community health initiatives.
DitchCarbon Score
How does Duopharma Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Duopharma Biotech's score of 29 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Duopharma Biotech's reported carbon emissions
In 2023, Duopharma Biotech, headquartered in Malaysia, reported total carbon emissions of approximately 42,000,000 kg CO2e, comprising 1,477,700 kg CO2e from Scope 1, 38,141,900 kg CO2e from Scope 2, and 4,085,800 kg CO2e from Scope 3 emissions. This marks a slight increase in Scope 1 emissions compared to previous years, while Scope 2 emissions have remained relatively stable. Over the years, Duopharma Biotech has shown fluctuations in its emissions. In 2022, the company reported total emissions of about 39,000,000 kg CO2e, with 1,287,990 kg CO2e from Scope 1, 38,062,900 kg CO2e from Scope 2, and 672,600 kg CO2e from Scope 3. The company’s emissions peaked in 2021 at approximately 36,000,000 kg CO2e, with significant contributions from both Scope 1 and Scope 2. Despite these figures, Duopharma Biotech has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates within an industry context that increasingly prioritises sustainability and carbon footprint reduction, yet it currently lacks formal commitments to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 21,800 | 00,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Duopharma Biotech is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
